X

Trial Profile

Phase II Study of Weekly Cabazitaxel for Advanced Prostate Cancer in 'Unfit' Hormone-Refractory Patients Previously Treated With Docetaxel

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabazitaxel (Primary) ; Prednisone
Indications Prostate cancer
Focus Therapeutic Use
Acronyms CABASEM

Most Recent Events

16 Feb 2019 Results evaluating efficacy of cabazitaxel in metastasic castration-resistant protate cancer patients presented at the 2019 Genitourinary Cancers Symposium
02 Nov 2017 Results assessing safety and efficacy published in the European Journal of Cancer
11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com